Inquiry Basket
| Catalog | Product Name | CAS Number |
|---|---|---|
| BADC-00546 | N-(2-(4-Chlorophenoxy)ethyl)-4-Formylbenzamide | 1226050-10-7 |
| N-(2-(4-Chlorophenoxy)ethyl)-4-Formylbenzamide is an aldehyde ADC linker featuring chlorophenoxy functionality, ideal for site-specific antibody conjugation and enhanced stability in ADC drug delivery systems. | Inquiry | |
| BADC-00547 | N-(2-(2,4-Difluorophenoxy)ethyl)-4-Formylbenzamide | 1226050-21-0 |
| N-(2-(2,4-Difluorophenoxy)ethyl)-4-Formylbenzamide is a fluorinated aldehyde ADC linker designed for selective conjugation and increased metabolic stability, improving antibody-drug conjugate efficacy and targeted payload release. | Inquiry | |
| BADC-00548 | N-(2-(4-Ethoxyphenoxy)ethyl)-4-Formylbenzamide | 1226072-27-0 |
| N-(2-(4-Ethoxyphenoxy)ethyl)-4-Formylbenzamide serves as an aldehyde-functionalized ADC linker, supporting rapid and selective antibody conjugation to optimize drug delivery efficiency in ADCs. | Inquiry | |
| BADC-00549 | 4-Formyl-N-(2-(3-isopropylphenoxy)ethyl)benzamide | 1226076-16-9 |
| 4-Formyl-N-(2-(3-isopropylphenoxy)ethyl)benzamide is an aldehyde-functional ADC linker facilitating precise antibody conjugation. The isopropylphenoxy moiety enhances hydrophobic interactions, boosting antibody-drug conjugate payload stability and tumor targeting. | Inquiry | |
| BADC-00550 | 4-Formyl-N-(2-(mesityloxy)ethyl)benzamide | 1226076-32-9 |
| 4-Formyl-N-(2-(mesityloxy)ethyl)benzamide is an aldehyde ADC linker with bulky mesityloxy groups, enhancing selective antibody conjugation and stability in ADC drug conjugation. | Inquiry | |
| BADC-00551 | N-(2-(3,4-dimethylphenoxy)ethyl)-4-formylbenzamide | 1226096-54-3 |
| N-(2-(3,4-dimethylphenoxy)ethyl)-4-formylbenzamide serves as a reactive aldehyde ADC linker for stable and selective conjugation to antibodies, improving payload attachment and targeted delivery in ADC therapeutics. | Inquiry | |
| BADC-00552 | 4-Formyl-N-(2-(o-Tolyloxy)ethyl)benzamide | 1226105-58-3 |
| 4-Formyl-N-(2-(o-Tolyloxy)ethyl)benzamide functions as an aldehyde ADC linker designed for stable, site-specific antibody conjugation, optimizing antibody-drug conjugate efficacy. | Inquiry | |
| BADC-00553 | N-(2-(3-Chlorophenoxy)ethyl)-4-Formylbenzamide | 1226200-04-9 |
| N-(2-(3-Chlorophenoxy)ethyl)-4-Formylbenzamide is an aldehyde-functionalized ADC linker that enables selective conjugation to antibodies, optimizing payload stability and targeted antibody-drug conjugate delivery. | Inquiry | |
| BADC-00554 | 4-Formyl-N-(2-(4-Isopropylphenoxy)ethyl)benzamide | 1226217-30-6 |
| 4-Formyl-N-(2-(4-Isopropylphenoxy)ethyl)benzamide is an aldehyde ADC linker optimized for selective bioorthogonal antibody conjugation, enhancing payload attachment specificity and ADC stability. | Inquiry | |
| BADC-00555 | 4-Formyl-N-(2-(2,3,6-Trimethylphenoxy)ethyl)benzamide | 1226218-43-4 |
| 4-Formyl-N-(2-(2,3,6-Trimethylphenoxy)ethyl)benzamide is an aldehyde-functional ADC linker facilitating site-specific antibody conjugation. Its trimethylphenoxy modification enhances linker stability, optimizing payload delivery in antibody-drug conjugates for targeted therapies. | Inquiry | |
| BADC-00556 | N-(2-(2-Ethoxyphenoxy)ethyl)-4-Formylbenzamide | 1226221-04-0 |
| N-(2-(2-Ethoxyphenoxy)ethyl)-4-Formylbenzamide is an aldehyde-bearing ADC linker designed for selective conjugation and enhanced antibody-drug conjugate stability, optimizing targeted drug delivery in cancer treatment. | Inquiry | |
| BADC-00557 | 4-Formyl-N-(2-(p-Tolyloxy)ethyl)benzamide | 1226279-82-8 |
| 4-Formyl-N-(2-(p-Tolyloxy)ethyl)benzamide is an aldehyde-based ADC linker that supports site-specific antibody conjugation and improves targeted payload release for enhanced ADC performance. | Inquiry | |
| BADC-00558 | N-(2-(3,5-Dimethylphenoxy)ethyl)-4-Formylbenzamide | 1226305-62-9 |
| N-(2-(3,5-Dimethylphenoxy)ethyl)-4-Formylbenzamide is an aldehyde-functionalized ADC linker that allows selective conjugation to antibody residues, enhancing antibody-drug conjugate targeting and payload stability. | Inquiry | |
| BADC-00559 | N-(2-(2,3-Dimethylphenoxy)ethyl)-4-Formylbenzamide | 1226305-75-4 |
| N-(2-(2,3-Dimethylphenoxy)ethyl)-4-Formylbenzamide is an aldehyde-functional ADC linker supporting selective conjugation and improved stability, boosting antibody-drug conjugate specificity and cytotoxic payload delivery. | Inquiry | |
| BADC-00560 | 4-Formyl-N-(2-(3-Methoxyphenoxy)ethyl)benzamide | 1226324-22-6 |
| 4-Formyl-N-(2-(3-Methoxyphenoxy)ethyl)benzamide serves as an aldehyde ADC linker enabling site-specific antibody conjugation, improving payload stability and antibody-drug conjugate performance in targeted therapies. | Inquiry | |
| BADC-00561 | N-(2-(2,5-Dimethylphenoxy)ethyl)-4-Formylbenzamide | 1226371-65-8 |
| N-(2-(2,5-Dimethylphenoxy)ethyl)-4-Formylbenzamide is an aldehyde-bearing ADC linker designed for selective conjugation to antibody residues, enhancing payload stability and antibody-drug conjugate targeting. | Inquiry | |
| BADC-00562 | 4-Formyl-N-(2-(2-Methoxyphenoxy)ethyl)benzamide | 1226372-18-4 |
| 4-Formyl-N-(2-(2-Methoxyphenoxy)ethyl)benzamide is an aldehyde-functional ADC linker enabling precise payload attachment and improved antibody-drug conjugate stability for targeted cancer therapies. | Inquiry | |
| BADC-00563 | N-(2-(2-Ethylphenoxy)ethyl)-4-Formylbenzamide | 1226394-63-3 |
| N-(2-(2-Ethylphenoxy)ethyl)-4-Formylbenzamide is an aldehyde-functionalized ADC linker optimized for site-specific bioorthogonal conjugation, improving antibody-drug conjugate stability and targeted drug release. | Inquiry | |
| BADC-00564 | N-(2-(2,4-Dimethylphenoxy)ethyl)-4-Formylbenzamide | 1226394-74-6 |
| N-(2-(2,4-Dimethylphenoxy)ethyl)-4-Formylbenzamide serves as a reactive ADC linker with aldehyde groups, facilitating selective antibody conjugation and enhanced targeted payload delivery. | Inquiry | |
| BADC-00565 | N-(2-(3,4-Difluorophenoxy)ethyl)-4-Formylbenzamide | 1226403-39-9 |
| Difluorophenoxy-functionalized aldehyde ADC linker designed for precise conjugation chemistry, enhancing payload attachment and controlled release in targeted antibody-drug conjugates. | Inquiry |
